2584-71-6 Usage
Description
cis-4-Hydroxy-D-proline, with the CAS number 2584-71-6, is a white powder compound that is an isomer of D-proline. It is characterized by the presence of a hydroxy group (R-configuration) at the 4-position of the pyrrolidine ring, which distinguishes it from other forms of proline. This unique structure endows cis-4-Hydroxy-D-proline with specific properties that make it valuable in various applications.
Uses
Used in Organic Synthesis:
cis-4-Hydroxy-D-proline is utilized as a key compound in organic synthesis, particularly for the development of novel molecules and pharmaceuticals. Its unique structure allows for the creation of a wide range of chemical entities with potential applications in various industries.
Used in Pharmaceutical Industry:
cis-4-Hydroxy-D-proline is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structural features make it a valuable building block for the development of new drugs with improved efficacy and selectivity.
Used in Research and Development:
In the field of research and development, cis-4-Hydroxy-D-proline serves as an important tool for studying the properties and functions of proline-containing peptides and proteins. Its unique structure allows researchers to investigate the effects of hydroxylation on protein folding, stability, and function.
Used in Cosmetics Industry:
cis-4-Hydroxy-D-proline may also find applications in the cosmetics industry, where it can be used as an active ingredient in anti-aging and skin care products. Its ability to modulate protein structure and function may contribute to the development of innovative cosmetic formulations with enhanced efficacy.
Biochem/physiol Actions
Cis-4-Hydroxy-D-proline may be used as a starting material for the 13-step synthesis of new conformationally restricted PNA adenine monomer and the synthesis of N-Benzyl pyrrolidinyl sordaricin derivatives. Cis-4-Hydroxy-D-proline is a substrate that may be used to study the specificity and kinetics of D-alanine dehydrogenase. Cis-4-Hydroxy-D-proline may be used to analyze the substrate specificity of amino acid transporter PAT1.
Check Digit Verification of cas no
The CAS Registry Mumber 2584-71-6 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,5,8 and 4 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 2584-71:
(6*2)+(5*5)+(4*8)+(3*4)+(2*7)+(1*1)=96
96 % 10 = 6
So 2584-71-6 is a valid CAS Registry Number.
InChI:InChI=1/C5H9NO3/c7-3-1-4(5(8)9)6-2-3/h3-4,6-7H,1-2H2,(H,8,9)/t3-,4+/m0/s1
2584-71-6Relevant articles and documents
-
Eguchi,Kakuta
, p. 1704,1707 (1974)
-
Chemoenzymatic Synthesis of cis-4-Hydroxy-D-proline
Sigmund, Amy E.,Hong, Wonpyo,Shapiro, Rafael,DiCosimo, Robert
, p. 587 - 590 (2001)
Candida antarctica lipase fraction B (CALB) catalyzed the hydrolysis of the (S)-enantiomer of racemic 4-oxo-1,2-pyrrolidinedicarboxylic acid dimethyl ester with high enantioselectivity (> 99.5% ee at 51% conversion). Regioselective hydrogenation of the isolated (R)-4-oxo-1,2-pyrrolidinedicarboxylic acid dimethyl ester produced (2R,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylic acid dimethyl ester in 98% yield, and subsequent hydrolysis of the ester and N-(alkoxycarbonyl) groups produced cis-4-hydroxy-D-proline in 98% yield and 96% de. Diastereomeric mixtures of 4-hydroxy-1,2-pyrrolidinedicarboxylic acid dimethyl esters were also resolved using CALB to produce cis-4-hydroxy-D-proline or trans-4-hydroxy-L-proline in 93 to > 99.5% diastereomeric excess.
INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)
-
Paragraph 339, (2018/02/28)
The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.
A short diastereoselective synthesis of cis-(2S,4S) and cis-(2R,4R)-4-hydroxyprolines
Gajare, Vikas S.,Khobare, Sandip R.,Malavika,Rajana, Nagaraju,Venkateswara Rao,Syam Kumar
supporting information, p. 3743 - 3746 (2015/06/08)
A concise synthesis of (2R,4R)-4-hydroxyproline (1) and (2S,4S)-4-hydroxyproline (2) has been developed in enantiomerically pure form from commercially available starting materials with excellent diastereoselectivity. The tightly bound chelation controlled transition state formed during the 5-exo-tet ring closure reaction is assumed to be the origin of high diastereoselectivity.